Navigation Links
Dr. Ramin Mirhashemi, MD of Gynecological Oncology Associates Discusses Uterine Fibroid Treatment with da Vinci Robotic Hysterectomy Surgery

TORRANCE, Calif., Sept. 28 /PRNewswire/ -- Uterine fibroids affect more than 30% of American women. However, many do not exhibit symptoms and therefore do not require fibroid treatment. Uterine fibroids treatment is only required if the fibroids are large enough to cause pressure on other organs (such as the bladder), grow rapidly, cause abnormal bleeding or cause problems with fertility. Uterine fibroids symptoms usually cause heavy or abnormal bleeding and discomfort, but the biggest concern for most women is difficulty in conceiving a baby.



"Minimally invasive uterine fibroids surgery has improved fibroid removal, with fewer complications and a faster recovery," says Dr. Ramin Mirhashemi of Gynecological Oncology Associates. "And with robotic hysterectomy, the technology only improves the procedure." With the use of da Vinci robotic surgery, the surgeon makes small incisions to insert tools and monitor the procedure through a tiny camera that is inserted into the patient.

Removing fibroids is important to preserve fertility and enable conception and implantation of the embryo in the uterine wall and facilitate a full-term, healthy pregnancy. Hysterectomy is the popular uterine fibroid treatment, but it also eliminates the ability for a woman to conceive a child. Traditional open surgery can also affect fertility because of scar tissue that builds from the incision in the uterus.

There are also other less invasive fibrosis treatments, which are less traumatic for the patient but still cannot preserve fertility. "Simply put, the uterus cannot be sewn back together well enough to ensure a full-term, healthy pregnancy," said Dr. Mirhashemi, who has the most experience in robotic surgery for gynecologic conditions in western United States. He and his staff at Gynecological Oncology Associates provide comprehensive care, professional expertise, and individualized attention to each patient seeking optimal gynecological care.

Thanks to robotic surgery, surgeons can use smaller tools for greater precision and range of motion. Surgeons like Dr. Mirhashemi sits at a nearby console looking through a monitor inside the patient and controlling the robot with hand controls and foot pedals. The camera gives the surgeon a 3D view of up to 15X magnification. "The robot helps me see very small blood vessels and nerves that I can spare, which results in very little damage to the surrounding tissue," said Mirhashemi.

Dr. Mirhashemi provides these helpful tips about uterine fibroids:

  • Always call your doctor if you have heavy bleeding, pain or reproductive issues.
  • Fibroids are usually benign, made up of fibrous tissue and smooth muscle.
  • Fibroids are usually found in the uterus, uterine wall or outside of the uterus.
  • Fibroids are usually more prevalent in women in their 40's.
  • They can grow as a single tumor or in clusters varying in size.
  • Uterine fibroids are the most common pelvic tumors seen by gynecologists.

"As the popularity of robotic surgery grows and gains acceptance, women can be assured of safer, effective fibroid removal with a greater chance of preserving fertility," said Dr. Mirhashemi.

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
2. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
3. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
4. US Oncology Pharmaceutical Distribution Service Wins National Safety Council Award
5. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
6. OncologySTAT Advisors Name Years Top Developments in Cancer Treatment and Research
7. First Coast Oncology to Offer Next Generation Proton Therapy
8. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
9. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
10. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
11. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced ... 29, 2015 at 11:00 a.m. Israel time, at ... 98 Yigal Allon Street, 36 th Floor, Tel Aviv, ... Eric Paneth and Izhak Tamir to the Board of ... as external directors; , approval of an amendment to certain terms ...
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier ... models, has promoted Melanie Aregger to serve as Chief Operating Officer. , ... the management team and was promoted to Head of InSphero Diagnostics in ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. ... that Mr. Pierre Laurin , President and Chief Executive ... the upcoming Piper Jaffray 27 th Annual Healthcare Conference ... December 1-2, 2015. st , at 8.50am ... meetings throughout the day. The presentation will be available live ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
Breaking Biology News(10 mins):